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Abstract
Background/Aims: Congenital hyperinsulinism (CHI) is a 
rare disease characterized by recurrent severe hypoglyce-
mia. In the diffuse form of CHI, pharmacotherapy is the pre-
ferred choice of treatment. Long-acting somatostatin ana-
logues have been used in children as off-label medication. 
However, the efficacy, outcomes, and adverse effect profiles 
of long-acting somatostatin analogues have not been de-
scribed in multicentered studies. The aim of this retrospec-
tive study is to summarize the experience with long-acting 
somatostatin analogues in a large group of children with 
CHI. Methods: Data were obtained retrospectively from 27 
patients with CHI who received long-acting somatostatin 
analogues in 6 different centers in Europe. These included 
information on glycemic stability, auxology, and adverse ef-
fect profile in clinical follow-up assessments. Results: Blood 
glucose control improved in most patients (89%). No life-
threatening side effects occurred. Thirteen patients (48%) 
experienced side effects; in 3 patients (11%), the side effects 
were the main reason for discontinuation of the treatment. 
The most frequent side effect was elevated liver enzymes 
(n = 10, 37%). Conclusion: Long-acting somatostatin ana-
logues are effective in glycemic control of patients with CHI. 
However, in 37% of all patients increased liver enzymes were 
observed. It is important to monitor liver function in all pa-
tients receiving long-acting somatostatin analogue therapy.
© 2017 S. Karger AG, Basel
Introduction
Congenital hyperinsulinism (CHI) is characterized by 
persisting hypoglycemia due to dysregulated and excess 
secretion of insulin [1]. It comprises a heterogeneous 
group of disorders, with the underlying genetic etiology 
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identified in approximately 40% of the patients. Until 
now, 9 different causative mutations have been described 
[2–4]. Early recognition and accurate management of 
CHI is of major importance in order to prevent brain 
damage and consequent neurodevelopmental problems 
[5–8].
In the focal form of CHI, hyperfunctioning pancreatic 
β-cells are localized in a solitary region of the pancreas, as 
a focal entity which can be detected by [F18]FDOPA-
PET/CT [9–11]. The treatment of choice for the focal 
form is surgical excision of the lesion [1, 5, 12, 13]. In-
stead, in patients with the diffuse form of CHI, the treat-
ment of choice consists of supplemental glucose and 
pharmacotherapy. Subtotal pancreatectomy is reserved 
for children in whom medical therapy is unable to achieve 
satisfactory glucose stability and/or is complicated by un-
acceptable side effects. However, this procedure inevita-
bly results in the development of diabetes mellitus at a 
later age and in many cases exocrine pancreatic dysfunc-
tion [5, 12, 14]. Therefore, medical treatment is preferred 
over subtotal pancreatectomy to preserve pancreatic 
function while ensuring glycemic stability to protect the 
developing brain in early childhood. However, the phar-
macological treatment of CHI is limited in choice and is 
often complicated by inefficacy and adverse events. Cur-
rent medications in use are not licensed in children with 
CHI. There are no randomized clinical trials of novel 
therapies in CHI, which may be due to several factors, in-
cluding the limited number of patients worldwide and the 
complexity of multicentered trial organization. Guide-
lines for medical therapy vary between centers with most 
treatment decisions being based primarily on expert 
opinion [15]. In the absence of robust evidence-based 
treatment regimens for CHI, it is important to collate in-
ternational experience in new therapies for optimum 
clinical management.
Recommended first-line pharmacological treatment 
consists of diazoxide in combination with the diuretic 
chlorothiazide [5, 11]. Diazoxide acts on the ATP sensi-
tive K+ (K-ATP) channel to reduce cell depolarization, 
thereby reducing insulin secretion [12]. However, not all 
patients respond to this treatment, particularly those with 
mutations in K-ATP channel genes (ABCC8, KCNJ11) [3, 
16]. Diazoxide therapy is often complicated by side ef-
fects, such as fluid retention, thrombocytopenia, hyper-
trichosis, and gastrointestinal dysmotility, which may 
lead to discontinuation of the treatment [12]. Nifedipine, 
a calcium antagonist, has been prescribed in the past as 
second-line treatment if children do not respond to di-
azoxide. However, nifedipine is rarely used in clinical 
practice as the clinical response to this drug is generally 
unsatisfactory [12]. Continuous subcutaneous glucagon 
is another therapy choice and has been utilized not only 
in initial therapy of hypoglycemia but also in long-term 
treatment of CHI [11, 12]. However, the commercially 
available preparation of glucagon precipitates in slow-
moving solutions within indwelling catheters causing ob-
struction and unreliable drug delivery [17]. Therefore, 
continuous glucagon is not currently envisaged for long-
term treatment of CHI.
Somatostatin is a hormone that preserves electrical 
stability of the pancreatic β-cell membrane and therefore 
inhibits the release of insulin. Octreotide, a short-acting 
somatostatin analogue, is commonly used as second-line 
treatment of CHI, in preference over nifedipine or con-
tinuous glucagon. [12, 18]. The half-life of octreotide is 
relatively short at around 100 min; therefore, octreotide 
has to be administered by continuous intravenous infu-
sion, frequent subcutaneous injections, or by continuous 
subcutaneous pump therapy [12]. Long-term subcutane-
ous octreotide treatment is demanding on the patient and 
family; multiple daily injections of home management or 
pump therapy are not always feasible. Side effects of oc-
treotide treatment include gastrointestinal dysmotility 
and tachyphylaxis, requiring escalating drug dosage to 
maintain efficacy. Gallbladder sludge and/or stones are 
commonly reported, while a reduction in growth velocity 
has been occasionally reported [5]. Octreotide has the po-
tential to reduce splanchnic circulation, with some groups 
reporting early- and late-onset necrotizing enterocolitis 
[19, 20]. Octreotide treatment can also cause drug-in-
duced elevated liver transaminases [21, 22], necessitating 
drug reduction or withdrawal.
Longer-acting somatostatin analogues have been sug-
gested as alternative treatment options for CHI, with the 
advantage of less frequent administration and possibly 
improving quality of life for patients and families [23–
26]. However, the experience of long-acting somatostatin 
analogues is limited to isolated case reports and small 
groups of patients. Two long-acting somatostatin ana-
logues are currently available, octreotide long-acting re-
lease (sandostatin-LAR) and somatuline autogel (lanreo-
tide) [23, 25], although both drugs are not licensed for use 
in children with CHI. Both analogues are injected either 
subcutaneously or intramuscularly every 4–6 weeks, rep-
licating therapy in adults with pituitary and gastrointes-
tinal neuroendocrine tumors. The experience with sand-
ostatin-LAR and lanreotide is limited to a few observa-
tional case reports in single centers reporting favorable 
outcomes [23–25]. The collective experience of long-act-
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ing somatostatin analogue therapy needs to be reviewed 
to understand long-term efficacy, side effects, and appli-
cation to CHI clinical management. In this study, we have 
collected information on the experience of long-acting 
somatostatin analogues in a large group of patients in sev-
eral European centers.
Patients and Methods
In this multicenter study, we report the use of long-acting so-
matostatin analogues in patients with CHI. We gathered a total of 
27 patients from 6 different pediatric departments in Europe – 8 
patients at the Otto-von-Guericke University in Germany, 7 pa-
tients at the Odense University Hospital in Denmark, 2 patients at 
the Royal Manchester Children’s Hospital in the United Kingdom, 
2 patients at the University Medical Center Utrecht, 2 patients at 
the Radboud University Medical Center in Nijmegen, and 6 pa-
tients at the University Medical Center Groningen, with the last 3 
centers being located in the Netherlands.
Ethical approval for the study in the Netherlands was obtained 
from the Medical Ethical Committee from the University of Gron-
ingen, The Netherlands. In Germany, ethical approval was ob-
tained according to national standards (IRB No. 27/08). In Den-
mark, the study was conducted according to the declaration of 
Helsinki and approved by The Research Ethics Committee (ref. 
No. 54947) and The Danish Data Protection agency (j. No. 
16/28242). For the United Kingdom, this study was supported by 
The North West Research Ethics Committee (project reference 
No.: 07/H1010/88).
Informed consent was not necessary for this study as was stated 
by the Ethical Committees; however, it was obtained from the par-
ents.
A uniform protocol was designed to collect specific standard-
ized information in all patients. Additional information was re-
corded in each treatment center depending on local protocols of 
treatment. Patient data were collected by the treating physician, 
assimilated by the corresponding author in anonymous fashion, 
and stored in a secure database. The following data were collected: 
age at manifestation, sex, height standard deviation scores before 
and during treatment, genetic confirmation of CHI, type, dose of 
somatostatin analogue, whether local anesthetics were used before 
administration of the drug, the number of hypoglycemic episodes 
per week before and during treatment and/or interpretation of the 
treating physician on hypoglycemia correction, and additional 
treatment options including pancreatic surgery. Drug side effect 
profile was based on biochemical testing of liver enzymes, thyroid 
function, insulin-like growth factor I, combined with ultrasound 
of the liver and gallbladder, and by noting abnormal clinical fea-
tures not explained by the CHI disease process.
Follow-up arrangements to monitor adverse drug reaction 
were performed by the treating physician. In most cases, they per-
formed an ultrasound of the liver and gallbladder in combination 
with biochemical testing every 3 months after initiating the treat-
ment.
None of the patients responded sufficiently to diazoxide, or di-
azoxide had to be terminated due to side effects. The medical treat-
ment was complemented with enriched feeds and enteral nutri-
tional therapy. All patients received octreotide for a period of 1–4 
weeks. When octreotide treatment achieved a stable glycemic sta-
tus, patients were switched to a long-acting somatostatin analogue. 
The decision on the type of long-acting somatostatin analogue de-
pended on the choice of the treating clinician and local prefer-
ences. Sandostatin-LAR was easier to access in Denmark. All oth-
er centers used lanreotide due to convenience of drug access and 
local pharmacy support.
All patients started treatment in their respective hospitals. If 
glucose levels stabilized in the follow-up period after the first injec-
tion, subsequent injections were provided in the community by 
home care nurses. Almost all patients received some form of local 
anesthesia before administration of sandostatin-LAR and lanreo-
tide. In some cases, depending on local policy, local anesthesia was 
combined with paracetamol or midazolam.
Sandostatin-LAR and lanreotide are produced in standard sy-
ringes of 10 and 60 mg, respectively. All patients started with the 
use of one standard syringe, which was administered once a month. 
Dose was not adjusted to the specific weight of the patients. There 
were a few exceptions to this rule; 4 patients had relatively low 
weights and a clinical decision was made in each case to administer 
half a syringe, i.e., a dose approximating 30 mg every 4 weeks. 
Other patients received lanreotide once every 6 weeks, which 
equals to 40 mg every 4 weeks.
Treatment response was defined as a reduction in hypoglyce-
mia (defined by a glucose level below 3.5 mmol/L) with 90% of 
blood glucose measurements being in the normal range or if there 
was less need for other medication or reliance on enteral nutri-
tional therapy.
Continuous subcutaneous glucose monitoring was performed 
occasionally during treatment. In most patients, this was not done 
on a regular basis and was reserved only for a period of 5–7 days. 
However, all patients had regular daily blood glucose monitoring 
using home glucose monitoring devices. These devices were not 
standardized; choice was dependent on local availability.
Results
In this study, we included 27 patients with CHI. Data 
derived from these patients are shown in Table 1. A total 
of 13 patients (48%) had ABCC8 mutations, of whom 2 
children had focal CHI and 11 children had diffuse CHI. 
Three patients (11%) had KCNJ11 mutations. Four pa-
tients (15%) had Beckwith-Wiedemann syndrome, 1 pa-
tient was diagnosed with congenital disorder of glycosyl-
ation type 1a, and in the remaining 6 patients (22%), no 
mutation was identified.
Patients were treated with a mean duration of 18 
months, with a range of 1–72 months. A total of 18 pa-
tients are presently being treated. Patients started long-
acting somatostatin analogues at a median age of 12 
months (range 2 months to 17 years). 
In total, 15 patients received monotherapy with a long-
acting somatostatin analogue combined with glucose-en-
Long-Acting Somatostatin Treatment in 
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Table 1. Detailed summary of the medical situation of all patients and the reported side effects
Pa-
tient
Age of
manifestation
Diagnosis/mutation Diffuse/
focal
Pancreatec-
tomy
Long-acting
somatostatin
Duration of
treatment
Reported side effects
1 After birth Beckwith-Wiedemann Diffuse No Lanreotide
(60 mg/month)
3 months Elevated γ-glutamyltransferase and 
gallstones
2 20 months Congenital disorder of glyco-
sylation type 1a
Diffuse No Lanreotide
(60 mg/month)
1 month Elevated liver enzymes (ASAT, ALAT, 
and AF)
3 After birth Heterozygous
KCNJ11 mutation
Diffuse No Lanreotide
(30 mg/month)
11 months
(ongoing)
None
4 After birth Beckwith-Wiedemann Diffuse No Lanreotide
(60 mg/month)
1 year Elevated liver enzymes and sludging of 
gallbladder, no gallstones
5 After birth Compound heterozygous
ABCC8 gene mutation
Diffuse Yes, partial Lanreotide
(60 mg/month)
10 months
(ongoing)
None
6 After birth Heterozygous ABCC8 gene 
mutation
Focal No, excision
focal lesion
Lanreotide
(60 mg/month)
2 months None
7 After birth No mutation Diffuse No Lanreotide
(60 mg/month)
4 years
(ongoing)
None
8 After birth Heterozygous ABCC8 gene 
mutation
Diffuse No Lanreotide
(60 mg/month)
3½ years None
9 After birth No mutation Diffuse Yes, partial Lanreotide
(60 mg/month)
2 years
(ongoing)
None
10 After birth Homozygous KCNJ11 gene 
mutation
Diffuse No Lanreotide
(60 mg/month)
4 years
(ongoing)
None
11 2 months Heterozygous ABCC8 gene 
mutation
Diffuse Yes, partial Lanreotide
(60 mg/6 weeks)
2 years
(ongoing)
Mildly elevated liver enzymes (ASAT + 
ALAT)
12 4 months Paternal heterozygous 
ABCC8 gene mutation
Focal Yes, excision
focal lesion
Lanreotide
(60 mg/month)
6 months Mildly elevated liver enzymes (ASAT + 
ALAT), low IGF-1
13 After birth Heterozygous ABCC8 gene 
mutation
Diffuse No Lanreotide
(60 mg/month)
6 months
(ongoing)
None
14 After birth Homozygous KCNJ11 gene 
mutation
Diffuse Yes, partial Lanreotide
(60 mg/month)
2 years
(ongoing)
Sludging of gallbladder + hepatomegaly
15 After birth Homozygous ABCC8
gene mutation
Diffuse No Lanreotide
(60 mg/month)
2 years Increased liver enzymes (AF). Reluctant 
to have injections, therefore difficulty in 
administering
16 6 months No mutation Diffuse No Sandostatin-LAR
(10 mg/month)
6 years Low IGF-1
17 After birth Heterozygous ABCC8 gene 
mutation
Diffuse Yes, subtotal Sandostatin-LAR
(10 mg/month)
2 years
(ongoing)
Thyroid hormone abnormalities (TSH 
depression), mildly elevated liver en-
zymes (ALAT)
18 After birth Heterozygous ABCC8 gene 
mutation
Diffuse Yes, subtotal Sandostatin-LAR
(5 mg/month)
1 year
(ongoing)
None
19 After birth No mutation Diffuse No Sandostatin-LAR
(7 mg/month)
1 year
(ongoing)
None
20 After birth Beckwith-Wiedemann Diffuse Yes, subtotal Sandostatin-LAR
(10 mg/month)
6 months
(ongoing)
Mildly elevated AF
21 4 days No mutation Diffuse No Sandostatin-LAR
(10 mg/month)
6 months
(ongoing)
None
22 4 months No mutation Diffuse Yes, subtotal Sandostatin-LAR
(5 mg/month)
4 months
(ongoing)
None
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riched feeds. Eight patients received combined treatment 
with diazoxide, and 2 patients continued treatment with 
nifedipine. Two patients discontinued treatment with 
long-acting somatostatin analogues because of normal-
ization of glucose levels; in both patients, normal glucose 
levels persisted after treatment withdrawal.
Two patients with focal CHI associated with paternal 
heterozygous mutations in ABCC8 were treated with lan-
reotide until surgical excision of the focal lesion was per-
formed. Among the remaining 25 patients with diffuse 
CHI, partial (approximately 30%) or subtotal pancreatec-
tomy (approximately 90%) was performed in 10 patients 
due to insufficient glucose control with medical treat-
ment. Three patients among this group had been treated 
with long-acting somatostatin analogue prior to surgery, 
while in 7 patients, treatment with long-acting soma-
tostatin analogue was initiated after pancreatectomy.
Long-acting somatostatin was noted to stabilize 
blood glucose levels to clinically acceptable levels in 24 
patients (89%). In the remaining 3 patients, treatment 
benefit was less clear and was suboptimal. In those pa-
tients, glucose levels were not maintained in 90% of 
measurements despite treatment with long-acting so-
matostatin analogues.
Side effects were noted in 13 of 27 patients (48%). 
There were no life threatening acute events which needed 
hospitalization. In 3 patients (11%), the side effects were 
the main reason for discontinuation of the medication. 
One patient suffered from recurrent abscess formation at 
the site of injection, which needed surgical intervention. 
In 2 patients, elevated liver enzymes were the reason for 
discontinuation.
The most frequently reported side effect was elevated 
liver enzymes (37% of all patients). One patient devel-
oped asymptomatic cholelithiasis, observed during ultra-
sound examination. After cessation of treatment, liver 
enzymes normalized, and after commencing ursodeoxy-
cholic acid, gallstones disappeared. Two patients devel-
oped biliary sludging in the gallbladder; in one, hepato-
splenomegaly was also present. In 5 patients mildly ele-
vated transaminases levels (defined by transaminase 
levels 50–80 U/L) were present. These patients continued 
treatment without further increase in liver enzymes. 
There was a substantial rise in transaminases in 2 pa-
tients. In 1 patient, liver enzymes had already been mild-
ly elevated prior to lanreotide therapy. Following lanreo-
tide treatment, liver enzymes increased significantly; as-
partate aminotransferase increased to 418 U/L and 
alanine aminotransferase increased to 950 U/L. After 
stopping lanreotide, all enzymes normalized within 3 
months. In another patient, an elevated transaminase >80 
U/L was noted following initiation of lanreotide therapy. 
However, as transaminase levels did not rise further with 
subsequent injections, treatment was continued for 1 
year. Following withdrawal of lanreotide treatment, 
transaminase levels normalized within 6 months. In 2 pa-
tients, alkaline phosphatase levels were raised, while 
transaminase and γ-glutamyltransferase levels remained 
Pa-
tient
Age of
manifestation
Diagnosis/mutation Diffuse/
focal
Pancreatec-
tomy
Long-acting
somatostatin
Duration of
treatment
Reported side effects
23 After birth ABCC8 gene mutation Diffuse No Lanreotide
(60 mg/month)
1 year and
9 months
(ongoing)
Local skin fibrosis
24 After birth Beckwith-Wiedemann Diffuse No Lanreotide (60–90  
mg/month)
1 year
(ongoing)
Mildly elevated liver enzmes (ASAT + 
AF)
25 After birth Homozygous ABCC8 gene 
mutation
Diffuse Yes, partial Lanreotide (30–60 
mg/month)
4 months Skin abscess formation
26 After birth Homozygous ABCC8 gene 
mutation
Diffuse Yes, partial Lanreotide (60–90 
mg/month)
2 years and
8 months
(ongoing)
Mildly elevated liver enzymes (ALAT)
27 After birth Homozygous ABCC8 gene 
mutation
Diffuse No Lanreotide
(60 mg/month)
8 weeks None
ASAT, aspartate aminotransferase; ALAT, alanine aminotransferase; AF, alkaline phosphatase; IGF-1, insulin-like growth factor 1; TSH, thyroid-
stimulating hormone.
Table 1 (continued)
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normal. Alkaline phosphatase levels spontaneously nor-
malized while on treatment.
In 1 patient, low serum thyroxine levels were reported, 
and he was treated with levothyroxine. A total of 2 pa-
tients reported adverse local skin reactions. Longitudinal 
growth was evaluated in 17 patients (63%). Although 7 
patients showed a mild decrease in growth, there were no 
patients in whom the height for age decreased below –2 
standard deviations. The weight for height was evaluated 
in 18 patients (67%). In most patients, the weight for 
height decreased to near normal. Only 3 patients contin-
ued to have a weight for height above 2 standard devia-
tions. During treatment, there were no patients who re-
ported tachyphylaxis. No patients developed signs of nec-
rotizing enterocolitis during treatment.
Discussion
The aim of this retrospective study is to share our in-
ternational experience with long-acting somatostatin an-
alogues in young patients with CHI. In our experience, 
long-acting somatostatin analogues are an effective treat-
ment option in most patients with diazoxide-unrespon-
sive CHI. Serious side effects did not occur; however, in 
37 percent of the patients, increased liver enzymes were 
observed. Minor side effects were observed in the major-
ity of the patients. We therefore recommend close moni-
toring of side effects during treatment with long-acting 
somatostatin analogues.
CHI is a relatively rare disease where hypoglycemia 
can be resistant to conventional treatment. Patients who 
are unresponsive to diazoxide can be treated with octreo-
tide either by frequent subcutaneous injections or by 
pump therapy. Both require intensive daily care, so alter-
native therapies are sought. Recently, there have been a 
few reports about the use of long-acting somatostatin an-
alogues in diazoxide-unresponsive patients [23–26]. At 
present, experience with this treatment is limited and 
data about side effects are lacking. Our study has provid-
ed an overview of efficacy and safety data in a retrospec-
tive and observational cohort.
The present study has several limitations, mostly due 
to its retrospective nature. The efficacy on glycemic pro-
file is based upon the interpretation of the treating physi-
cian, since continuous glucose monitoring data before 
and during treatment were not available in all the pa-
tients. In a previous study, a decreased incidence of hypo-
glycemic episodes had been observed in 6 patients who 
switched from octreotide 3–4 times a day to lanreotide 
[24]. Another study described 2 patients with adequate 
glucose regulation on continuous octreotide therapy, 
with comparable regulation after switching to lanreotide 
[23]. Our findings in a larger cohort are similar to those 
previously described.
Patients included in this study were treated with a 
long-acting somatostatin analogue, either lanreotide or 
sandostatin-LAR. Both are octapeptides and proved ef-
fective in glucose regulation, but differ by their pharma-
cokinetic profiles [27]. Lanreotide starts with a rapid-re-
lease phase, followed by a long-lasting phase of slow re-
lease. Sandostatin-LAR is formulated as microspheres of 
biodegradable polymer containing the active peptides. 
After a single intramuscular injection, the plasma con-
centration remains very low during the first 2 weeks and 
then increases quickly to reach a plateau, which remains 
stable between 3 and 4 weeks [26, 27]. There is no spe-
cific data available about the difference in efficacy or side 
effects between the different long-acting somatostatin an-
alogues. Further research is needed to evaluate which one 
is more preferable in children with CHI; our study was 
not designed to address the efficacy and safety perfor-
mance of one over the other. In the present study, in-
creased liver enzymes were observed in the lanreotide 
group as well as in the sandostatin-LAR group. Recently, 
a new somatostatin analogue, called pasireotide, has been 
available with a more specific binding to somatostatin re-
ceptor subtypes [28]. In the future, this could also be of 
use in the treatment of CHI, with potentially fewer side 
effects. However, pasireotide has not been used in chil-
dren for any medical indication. 
The most favorable dose of lanreotide in terms of ef-
ficacy and side effects is not known. One study used 30 
mg [23] and another study used 60 mg [24], with no com-
parable data to choose a higher or lower dose. In our 
study, most patients received lanreotide 60 mg adminis-
tered as the entire contents of a prefilled syringe. Our 
study highlights the need to undertake a rigorous trial 
with efficacy and safety outcomes to standardize drug 
dosage of lanreotide.
Somatostatin has inhibitory effects on gastrointestinal 
motility, gallbladder contractility, and splanchnic blood 
flow, which can result in gastrointestinal symptoms, cho-
lelithiasis, hepatitis, and necrotizing enterocolitis. There-
fore, there are theoretical grounds to be cautious about 
the prescription of somatostatin analogues to very young 
patients or patients with compromised intestinal perfu-
sion. However, none of our patients developed necrotiz-
ing enterocolitis. Nevertheless, it would be prudent to 
limit long-acting somatostatin analogue treatment to in-
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fants beyond the neonatal period and avoid treatment in 
those predisposed to necrotizing enterocolitis.
The most common side effect in the present study was 
the increase of hepatic enzymes, a sign of hepatitis. Short-
acting somatostatin analogues are well recognized to 
cause hepatitis, manifested by elevated liver enzymes 
(transaminases and γ-glutamyltransferase) in patients 
with CHI [21, 22]. As sandostatin-LAR and lanreotide are 
long acting and depot preparations of somatostatin ana-
logues, liver enzyme elevation is not an unexpected ad-
verse reaction, resulting from the long transit time of the 
active drug in the body. Earlier research reported that this 
side effect is reversible after cessation of treatment [15]. 
In patients who stopped treatment, liver enzymes nor-
malized, suggesting that drug-induced hepatitis is revers-
ible.
Since a major part of the treatment of CHI consists of 
high concentration of carbohydrate feeds, almost all pa-
tients developed obesity prior to treatment with long-act-
ing somatostatin analogue therapy. Subsequent treat-
ment with long-acting somatostatin analogues did not 
increase the risk of obesity.
In conclusion, the summary of our patient data showed 
that monthly injections of long-acting somatostatin ana-
logues were effective in maintaining euglycemia without 
serious side effects in the majority of patients. Increased 
liver enzymes were observed in 37% of the patients, which 
should be carefully monitored.
Based on our common experience, we recommend the 
following:
 − Consider long-acting somatostatin analogues in di-
azoxide-unresponsive patients after a trial of treat-
ment with octreotide. If octreotide is effective and no 
severe side effects occur after a trial period, lanreotide 
(start dosage 30–60 mg subcutaneously every 4 weeks) 
or sandostatin-LAR (start dosage 10 mg intramuscu-
larly every 4 weeks) could be considered.
 − Avoid treatment with somatostatin analogues in pa-
tients with an increased risk of necrotizing enterocoli-
tis. 
 − Patients receiving long-acting somatostatin analogue 
treatment should be monitored by blood glucose mon-
itoring and/or continuous subcutaneous glucose mon-
itoring to ensure satisfactory treatment response.
 − Monitor liver enzymes every 4–6 weeks and repeat ab-
dominal ultrasound every 3–6 months. If (asymptom-
atic) cholelithiasis is present, ursodeoxycholic acid 
may be added to the treatment regimen. 
 − Monitor growth and thyroid function at least 6-month-
ly. If tests indicate hypothyroxinemia, levothyroxine 
treatment may be required.
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